HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

Benzinga · 2d ago
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $95 to $165.